The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer
1 other identifier
interventional
150
1 country
1
Brief Summary
Spectral CT was used to prospectively collect medical images and clinical data related to gastric cancer, evaluate the effect of image quality in the diagnosis of gastric cancer, and evaluate the application value in the accurate staging of gastric cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable gastric-cancer
Started Jun 2025
Shorter than P25 for not_applicable gastric-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2025
CompletedFirst Posted
Study publicly available on registry
May 18, 2025
CompletedStudy Start
First participant enrolled
June 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
May 18, 2025
April 1, 2025
12 months
May 9, 2025
May 16, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Pathological TNM staging
Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
1 day
Study Arms (1)
The application value of spectral CT in the accurate staging of gastric cancer
EXPERIMENTALProspectively collect medical images and clinical data related to gastric cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of gastric cancer.Patients diagnosed with gastric cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of gastric cancer patients was assessed by two radiologists, and finally statistical analysis was performed.
Interventions
CT scan of the abdomen outside of standard treatment options
Eligibility Criteria
You may qualify if:
- (a)Patients with pathologically confirmed gastric cancer;
- (b) aged ≥ 18 years old;
- (c) have not received chemoradiotherapy or surgery.
You may not qualify if:
- (a)Combined with other primary tumors;
- (b) The image quality does not meet the diagnostic criteria;
- (c)Those who cannot tolerate CT examination.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Yunnan Cancer Hospital
Kunming, Yunnan, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Lianhua Ye
Ethics Committee of Yunnan Provincial Cancer Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2025
First Posted
May 18, 2025
Study Start
June 1, 2025
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
May 31, 2026
Last Updated
May 18, 2025
Record last verified: 2025-04